Skye Bioscience, Inc.
Clinical-stage biotech developing treatments for obesity and metabolic diseases.
SKYE | US
Overview
Corporate Details
- ISIN(s):
- US83086J2006
- LEI:
- Country:
- United States of America
- Address:
- 11250 EL CAMINO REAL, SUITE 100, 92130 SAN DIEGO
- Website:
- https://skyebioscience.com/
Description
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for obesity and other metabolic diseases. The company's strategy involves advancing first-in-class molecules that modulate G-protein coupled receptors (GPCRs). Its lead drug candidate, nimacimab, is a peripherally-acting antibody that inhibits the cannabinoid receptor 1 (CB1). Nimacimab is designed to target CB1 receptors in peripheral tissues like adipose, liver, and muscle, with the goal of reducing hunger and increasing energy expenditure while limiting central nervous system exposure. This mechanism is being investigated for its potential as a complementary approach to existing obesity therapies, aiming to provide more sustainable weight loss, improved body composition, and better tolerability. Nimacimab is being evaluated in Phase 2 clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Skye Bioscience, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Skye Bioscience, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Skye Bioscience, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
